biotech / news / / The Hindu Business Line
Novo Nordisk is seeing brisk early demand for its new weight-loss pill.
Novo's oral Wegovy pill reached about 721,000 U.S. prescriptions in Q1, beating expectations.
KEY POINTS
- IQVIA data suggest actual prescription numbers may be higher, excluding some telehealth channels.
- Approximately 450,000 prescriptions were for the cheapest starter dose, potentially reducing overall revenue.
- The introduction of Eli Lilly's rival pill, Foundayo, in April ended Novo's U.S. exclusivity.
- Analysts warn strong prescription growth may mask revenue impact from slow dose escalation and price pressures.
COMPANIES
Summarized by Newsio from The Hindu Business Line. How we summarize →